Pregnancy: There are limited post marketing data on the use of domperidone in pregnant women. Therefore, Motilium Tablets should only be used during pregnancy when justified by the anticipated therapeutic benefit.
Breast Feeding: Domperidone is excreted in human milk and breast-fed infants receive less than 0.1% of the maternal weight-adjusted dose. Occurrence of adverse effects, in particular cardiac effects cannot be excluded after exposure via breast milk. A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from domperidone therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. Caution should be exercised in case of QTc-prolongation risk factors in breast-fed infants.